We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Boston Scientific (BSX - Free Report) closed the most recent trading day at $91.99, moving +0.77% from the previous trading session. This change outpaced the S&P 500's 1.11% loss on the day. At the same time, the Dow lost 0.42%, and the tech-heavy Nasdaq lost 1.89%.
The medical device manufacturer's stock has climbed by 2.9% in the past month, exceeding the Medical sector's loss of 6.22% and the S&P 500's loss of 1.7%.
Investors will be eagerly watching for the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 5, 2025. The company is expected to report EPS of $0.65, up 18.18% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $4.4 billion, up 18.15% from the year-ago period.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Boston Scientific. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 2.18% higher. As of now, Boston Scientific holds a Zacks Rank of #2 (Buy).
Investors should also note Boston Scientific's current valuation metrics, including its Forward P/E ratio of 32.92. This denotes a premium relative to the industry's average Forward P/E of 18.9.
One should further note that BSX currently holds a PEG ratio of 2.39. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 2.1.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 145, positioning it in the bottom 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Boston Scientific (BSX) Gains As Market Dips: What You Should Know
Boston Scientific (BSX - Free Report) closed the most recent trading day at $91.99, moving +0.77% from the previous trading session. This change outpaced the S&P 500's 1.11% loss on the day. At the same time, the Dow lost 0.42%, and the tech-heavy Nasdaq lost 1.89%.
The medical device manufacturer's stock has climbed by 2.9% in the past month, exceeding the Medical sector's loss of 6.22% and the S&P 500's loss of 1.7%.
Investors will be eagerly watching for the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 5, 2025. The company is expected to report EPS of $0.65, up 18.18% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $4.4 billion, up 18.15% from the year-ago period.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Boston Scientific. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 2.18% higher. As of now, Boston Scientific holds a Zacks Rank of #2 (Buy).
Investors should also note Boston Scientific's current valuation metrics, including its Forward P/E ratio of 32.92. This denotes a premium relative to the industry's average Forward P/E of 18.9.
One should further note that BSX currently holds a PEG ratio of 2.39. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 2.1.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 145, positioning it in the bottom 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.